Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

90.14USD
15 Nov 2018
Change (% chg)

$1.83 (+2.07%)
Prev Close
$88.31
Open
$87.63
Day's High
$90.29
Day's Low
$85.96
Volume
2,276,945
Avg. Vol
1,527,451
52-wk High
$125.84
52-wk Low
$77.50

Select another date:

Fri, Nov 2 2018

Humira biosimilars available at up to 80 pct discount in Europe-AbbVie

Nov 2 AbbVie Inc said on Friday rival biosimilar versions of its best-selling drug Humira were available in Europe at discounts ranging from 10 percent to 80 percent.

AbbVie expects double-digit earnings growth in 2019

Nov 2 AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union.

AbbVie lifts profit target after cancer drug powers third-quarter beat

Nov 2 AbbVie Inc beat Wall Street estimates for third-quarter profit and raised its earnings forecast for the year on Friday, driven by strong sales of blockbuster cancer medicine Imbruvica.

AbbVie, Roche combo treatment meets main goal of leukemia trial

(This Oct 31 story corrects paragraph one to say targeted therapy, not immunotherapy)

CORRECTED-AbbVie, Roche combo treatment meets main goal of leukemia trial

Oct 31 AbbVie Inc and Roche Holding AG said on Wednesday their targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker's cancer drug in a late-stage trial.

FDA approves Novartis' copy of AbbVie bestseller Humira

The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday.

FDA approves Novartis' copy of AbbVie bestseller Humira

Oct 31 The U.S. Food and Drug Administration (FDA) has approved Novartis AG's copy of Humira, the world's bestselling prescription medicine developed by U.S.-based AbbVie Inc, the agency's website showed on Wednesday.

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Abbott, AbbVie settle TriCor marketing case for $25 million

Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln

Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.

Select another date: